Eugia Pharma Receives USFDA Approval for Isoproterenol HCl Injection 0.2 mg/1 mL and 1 mg/5 mL Ampoules

Eugia Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Isoproterenol HCl Injection 0.2 mg/1 mL and 1 mg/5 mL Ampoules.

Indications for this product include:

• Mild or transient episodes of heart block that do not require electric shock or pacemaker therapy;
• Serious episodes of heart block and Adams-Stokes attacks except when caused by ventricular tachycardia or fibrillation (see CONTRAINDICA­TIONS);
• Cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, are available (see CONTRAINDICATIONS);
• Bronchospasm occurring during anesthesia;
• Adjunct to fluid and electrolyte replacement therapy and other drugs and procedures for hypovolemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure, and cardiogenic shock (see WARNINGS).

Refer to package insert for full prescribing information.